COPERNICUS: A Phase 2b, Open-Label, Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment
Condition: Non-Small Cell Lung Cancer
Sponsor: Janssen Research & Development, LLC
Full Title
Protocol 61186372NSC2012: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in
Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with
Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or
Metastatic Non-Small Cell Lung Cancer
Study Treatment
Amivantamab, a bispecific antibody targeting EGFR and MET in combination with lazertinib, an EGFR tyrosine kinase inhibitor.
Eligibility/Info
Eligible patients will have an advanced/metastatic non-small cell lung cancer with an EGFR exon 19 deletion or EGFR L858R mutation and will not have received systemic anticancer therapy in the advanced/metastatic setting.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
